Figure 1: Longitudinal trends in plasminogen activator inhibitor-1 (PAI-1) levels. | Scientific Reports

Figure 1: Longitudinal trends in plasminogen activator inhibitor-1 (PAI-1) levels.

From: Link between plasminogen activator inhibitor-1 and cardiovascular risk in chronic hepatitis C after viral clearance

Figure 1

The included patients with chronic hepatitis C were stratified according to (A) sex (male: 1; female: 0), (B) PAI-1-rs-1799889 genotype (4 G/4 G genotype: 1; non-4G/4 G genotype: 0) and (C) IFNL3-rs-12979860 genotype (CC genotype: 1; non-CC genotype: 0). The blood-drawing time points were as follows: 1, 2 weeks before therapy; 2, after 4 weeks of therapy; 3, after 12 weeks of therapy; 4, after 24 weeks of therapy; 5, after 36 weeks of therapy; 6, after 48 weeks of therapy; 7, after 60 weeks of therapy; and 8, after 72 weeks of therapy.

Back to article page